A recent analysis of the spectrum of phenotypes associated with OMOD2 and FZD2 mutations concluded that these are clinically indistinguishable from AD-RS and that OMOD2 should rather be considered as FZD2-associated AD-RS, contributing to ∼14% of all RS cases (Zhang et al., 2022; Zhang et al., 2021). This evidence concerns the gene FZD2 and Alzheimer disease.